Page not found

As biologics, biomarker-enriched trials and real-world evidence reshape the COPD landscape, sponsors face both new opportunities and increasing complexity. Success depends on translating these advances into effective cli...

As biotech confidence returns and deal activity accelerates, companies have an opportunity to position themselves for the next phase of growth. In a new BioPharma Dive article, Deepali Suri, President of ICON Biotech, s...

We are proud to share that ICON has been named a Winner for Organisational Excellence for the second year running at the GCC India Workplace Innovation Summit & Awards 2026. This recognition celebrates organisations red...

Sustainability remains central to how we operate, innovate and support our communities at ICON. Being named in TIME’s World’s Most Sustainable Companies 2026 for a second year underscores our ICON Cares’ focus on respon...

Vaccines save millions of lives each year and help protect communities from preventable diseases. In support of National Immunisation Awareness Month, ICON is proud to have participated in 147 vaccine studies across key ...

Policy binders aren't enough to protect patients on neurologic monoclonal antibodies (mAbs). Clinical practices must embed automated safety rules, like therapy holds for active infections, directly into EHR systems. Disc...

Heart failure affects millions of people worldwide and can significantly impact quality of life. Research into new treatment approaches remains critical to improving outcomes and expanding options for patients living wit...

Colleagues at our Mexico office put their gaming skills to the test earlier this month at the ICON4U Super Smash Bros. Ultimate Tournament. Organised by the ICON4U Engagement and Celebrations Chapter, the event welcomed...

ctDNA holds significant potential for accelerating cancer drug development, but acceptance as a primary surrogate endpoint remains a major regulatory challenge. ICON’s Bea Mann examines the scientific, regulatory and evi...

Modern Alzheimer's management requires an "MRI metronome". For anti-amyloid therapies, rigid adherence to routine MRI schedules is essential to detect dangerous amyloid-related imaging abnormalities (ARIA). Read our arti...

Talent shortages are emerging as a critical challenge for Asia-Pacific biotech companies. A recent ICON survey found that biotech professionals in APAC were nearly three times more likely than their global peers to repor...

Latest issue now available. Join thousands of subscribers who have discovered the convenience of our free monthly publication, by signing up today. https://ow.ly/hTYQ50Zu7sT Compiled and collated by ICON’s Regulatory I...